C4X Discovery Holdings plc announced that it has received a milestone payment of $11 million from AstraZeneca triggered by preclinical progress of C4XD's NRF2 Activator programme. Under the terms of the licensing agreement announced in November 2022, C4XD received an initial $2 million upfront payment and is potentially entitled to receive up to $400 million in preclinical, clinical development and commercial milestones, and to tiered mid-single digit royalties on future sales. AstraZeneca is developing C4XD's former NRF2 Activator programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12 GBX | +27.32% | +45.90% | +33.33% |
Apr. 25 | Norcros sells Johnson Tiles UK; Trifast trading well | AN |
Apr. 25 | C4X Discovery Set for Friday Delisting from London Bourse's AIM | MT |
1st Jan change | Capi. | |
---|---|---|
+33.33% | 37.7M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- C4XD Stock
- News C4X Discovery Holdings plc
- C4X Discovery Holdings plc Receives Milestone Payment of $11 Million from AstraZeneca